Cancer clinical trials in the region Provence-Alpes-Côte d'Azur

424 currently recruiting clinical trials
Region Provence-Alpes-Côte d'Azur
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT04657068 #2024-511534-12-00
Parties A1, A2, A3 (escalade de dose)
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
ATM
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Artios Pharma Ltd
Phase 1 / Phase 2 Endometrial cancer #NCT04657068 #2024-511534-12-00
Dose d'expansion Partie B3
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
ATM
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Artios Pharma Ltd
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT04657068 #2024-511534-12-00
Dose d'expansion Partie B1
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
ATM
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Artios Pharma Ltd
Phase 1 / Phase 2 Colon cancer Rectal cancer #NCT04657068 #2024-511534-12-00
Dose d'expansion Partie B5
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required genetic anomalies
ATM
Required number of previous lines of therapy for current stage of disease
2
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Artios Pharma Ltd
Phase 1 / Phase 2 Pancreas cancer #NCT04657068 #2024-511534-12-00
Dose d'expansion Partie B6
Required histologic sub types
Adenocarcinoma Other
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
ATM
Required number of previous lines of therapy for current stage of disease
1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Artios Pharma Ltd
Phase 1 / Phase 2 Ovarian / Fallopian tubes / Peritoneum cancer #NCT04657068 #2024-511534-12-00
Dose d'expansion Partie B2
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at localized stage
Chemotherapy Targeted therapy
Required previous treatments at advanced or metastatic stage
Chemotherapy Targeted therapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Artios Pharma Ltd
Phase 1 / Phase 2 Lung cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Head and neck cancer #NCT06923761 #2023-504845-30-00
Module 2 Cohorte 3 Tumeurs solides avec un TMB médian modéré à élevé
Required histologic types
NSCLC (Non-Small Cell Lung Cancer) Stomach Oesogastric junction Esophagus Invasive bladder cancer Oral cavity Nasopharynx Oropharynx Hypopharynx Larynx Nasal cavities and sinuses
Required histologic sub types
Adenocarcinoma Squamous cell carcinoma Urothelial carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Grey Wolf Therapeutics
Phase 1 / Phase 2 Acute leukemia #NCT05768035
Required histologic types
Acute lymphoblastic leukemia (ALL) Acute myeloid leukemia (AML)
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive Allogeneic stem cell transplant
4 recruiting sites
Smart Immune SAS
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06818643 #2024-516817-19-00
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Merck Sharp & Dohme LLC
Phase 1 / Phase 2 Lung cancer Prostate cancer Stomach and esophageal cancer #NCT05434234
Required histologic types
SCLC (Small Cell Lung Cancer) NSCLC (Non-Small Cell Lung Cancer) Esophagus
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
MediLink Therapeutics (Suzhou) Co., Ltd.